[1] VANNESTE D,VERSCHEURE E,SRINIVASAN A N,et al.Systematic review of genotoxicity induced by occupational exposure to antineoplastic drugs[J].Arch Toxicol,2023,97(6):1453-1517. [2] LESO V,SOTTANI C,SANTOCONO C,et al.Exposure to antineoplastic drugs in occupational settings:A systematic review of biological monitoring data[J].Int J Environ Res Public Health,2022,19(6):3737. [3] CONNOR T H,LAWSON C C,POLOVICH M,et al.Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings:A review of the evidence[J].J Occup Environ Med,2014,56(9):901-910. [4] VILLARINI M,GIANFREDI V,LEVORATO S,et al.Occupational exposure to cytostatic/antineoplastic drugs and cytogenetic damage measured using the lymphocyte cytokinesis-block micronucleus assay:A systematic review of the literature and meta-analysis[J].Mutat Res Rev Mutat Res,2016,770(Pt A):35-45. [5] HUANG H,GU Y,LIU S,et al.The meta-analysis of cytogenetic biomarkers as an assessment of occupational risk for healthcare workers exposed to antineoplastic drugs[J].Int Arch Occup Environ Health,2023,96(6):785-796. [6] FRANSMAN W,VERMEULEN R,KROMHOUT H.Dermal exposure to cyclophosphamide in hospitals during preparation,nursing and cleaning activities[J].Int Arch Occup Environ Health,2005,78(5):403-412. [7] KROMHOUT H,HOEK F,UITTERHOEVE R,et al.Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers.Applying a conceptual model to the results of three workplace surveys[J].Ann Occup Hyg,2000,44(7):551-560. [8] SESSINK P J,CERNÁ M,RÖSSNER P,et al.Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents[J].Mutat Res,1994,309(2):193-199. [9] FRANSMAN W,ROELEVELD N,PEELEN S,et al.Nurses with dermal exposure to antineoplastic drugs:Reproductive outcomes[J].Epidemiology,2007,18(1):112-119. [10] KOPP B,SCHIERL R,NOWAK D.Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings[J].Int Arch Occup Environ Health,2013, 86(1):47-55. [11] HON C Y,TESCHKE K,SHEN H,et al.Antineoplastic drug contamination in the urine of Canadian healthcare workers[J].Int Arch Occup Environ Health,2015,88(7):933-941. [12] 生态环境部.重点管控新污染物清单(2023年版)[J].中华人民共和国国务院公报,2023(5):19-24. [13] LI B,HU K,LYSENKO V,et al.A scientometric analysis of agricultural pollution by using bibliometric software VoSViewer and HistciteTM[J].Environ Sci Pollut Res Int,2022,29(25):37882-37893. [14] PETHRAN A,SCHIERL R,HAUFF K,et al.Uptake of antineoplastic agents in pharmacy and hospital personnel.Part I:monitoring of urinary concentrations[J].Int Arch Occup Environ Health,2003,76(1):5-10. [15] TURCI R,SOTTANI C,et al.SPAGNOLI G.Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents:A review of analytical methods[J].J Chromatogr B Analyt Technol Biomed Life Sci,2003,789(2):169-209. [16] SCHMAUS G,SCHIERL R,FUNCK S.Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry[J].Am J Health Syst Pharm,2002,59(10):956-961. [17] TURCI R,SOTTANI C,RONCHI A,et al.Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents[J].Toxicol Lett,2002,134(1-3):57-64. [18] HEDMER M,TINNERBERG H,AXMON A,et al.Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital[J].Int Arch Occup Environ Health,2008,81(7):899-911. [19] CONNOR T H,DEBORD D G,PRETTY J R,et al.Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers[J].J Occup Environ Med,2010,52(10):1019-1027. [20] SCHIERL R,BÖHLANDT A,Nowak D.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies[J]. Ann Occup Hyg,2009,53(7):703-711. [21] MCDIARMID M A,OLIVER M S,ROTH T S,et al.Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs[J].J Occup Environ Med,2010,52(10):1028-1034. [22] YOSHIDA J,KODA S,NISHIDA S,et al.Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan[J].J Oncol Pharm Pract,2011,17(1):29-38. [23] CHU W C,HON C Y,DANYLUK Q,et al.Pilot assessment of the antineoplastic drug contamination levels in British columbian hospitals pre- and post-cleaning[J].J Oncol Pharm Pract,2012,18(1):46-51. [24] KIFFMEYER T K,TUERK J,HAHN M,et al.Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project[J].Ann Occup Hyg,2013,57(4):444-455. [25] HON CY,TESCHKE K,CHU W,et al.Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals[J].J Occup Environ Hyg,2013,10(7):374-383. [26] SUSPIRO A,PRISTA J.Biomarkers of occupational exposure do anticancer agents:A minireview[J].Toxicol Lett,2011,207(1):42-52. [27] HON C Y,TESCHKE K,DEMERS P A,et al.Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system[J].Ann Occup Hyg,2014,58(6):761-770. [28] CONNOR T H,ZOCK M D,SNOW A H.Surface wipe sampling for antineoplastic(chemotherapy) and other hazardous drug residue in healthcare settings:Methodology and recommendations[J].J Occup Environ Hyg,2016,13(9):658-667. [29] KIBBY T.A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs[J].J Occup Environ Hyg,2017,14(3):159-174. [30] POWER L A,COYNE J W.ASHP guidelines on handling hazardous drugs[J].Am J Health Syst Pharm,2018,75(24):1996-2031. [31] CHAUCHAT L,TANGUAY C,CARON N J,et al.Surface contamination with ten antineoplastic drugs in 83 Canadian centers[J]. J Oncol Pharm Pract,2019,25(5):1089-1098. [32] DUGHERI S,BONARI A,POMPILIO I,et al.Analytical strategies for assessing occupational exposure to antineoplastic drugs in healthcare workplaces[J].Med Pr,2018,69(6):589-604. [33] SIMON N,ODOU P,DECAUDIN B,et al.Efficiency of degradation or desorption methods in antineoplastic drug decontamination:A critical review[J].J Oncol Pharm Pract,2019,25(4):929-946. [34] ROUSSEL C,WITT K L,SHAW P B,et al.Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs[J].Mutat Res Rev Mutat Res,2019,781:207-217. [35] GRAEVE C U,MCGOVERN P M,ALEXANDER B,et al.Occupational exposure to antineoplastic agents[J].Workplace Health Saf,2017,65(1):9-20. [36] VERSCHEURE E,CRETA M,VANOIRBEEK J,et al.Environmental contamination and occupational exposure of algerian hospital workers[J].Front Public Health,2020,8:374. [37] LABRÈCHE F,OUELLET C,ROBERGE B,et al.Occupational exposure to antineoplastic drugs:what about hospital sanitation personnel?[J].Int Arch Occup Environ Health,2021,94(8):1877-1888. [38] DELAFOY C,ROUSSY C,HUDON A F,et al.Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers[J].J Oncol Pharm Pract,2023,29(2):338-347. [39] ARNOLD S,KAUP H M.Assessing variability of antineoplastic drugs handling practices in clinical settings[J].J Occup Environ Hyg,2019,16(12):757-762. [40] SOTTANI C,GRIGNANI E,CORNACCHIA M,et al.Occupational exposure assessment to antineoplastic drugs in nine italian hospital centers over a 5-year survey program[J]. Int J Environ Res Public Health,2022,19(14):8601. [41] SCHIERL R,BÖHLANDT A,NOWAK D.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies[J].Ann Occup Hyg,2009,53(7):703-711. [42] SOTTANI C,PORRO B,COMELLI M,et al.An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers[J].J Chromatogr B Analyt Technol Biomed Life Sci,2010,878(27):2593-2605. [43] SOTTANI C,GRIGNANI E,ODDONE E,et al.Monitoring Surface contamination by antineoplastic drugs in italian hospitals:performance-based hygienic guidance values(HGVs) project[J].Ann Work Expo Health,2017,61(8):994-1002. [44] QUARTUCCI C,ROONEY J P K,NOWAK D,et al.Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies[J].Int Arch Occup Environ Health,2023,96(5):675-683. [45] ROMBALDI F,CASSINI C,SALVADOR M,et al.Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week[J].Mutagenesis,2009, 24(2):143-148. [46] SANTOS A N,OLIVEIRA R J,PESSATTO L R,et al.Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents[J].Int J Pharm Pract,2020,28(5):506-511. [47] GIANFREDI V,NUCCI D,FATIGONI C,et al.Extent of primary DNA damage measured by the comet assay in health professionals exposed to antineoplastic drugs:A systematic review and meta-analysis[J].Int J Environ Res Public Health,2020,17(2):523. [48] URSINI C L,OMODEO SALÈ E,FRESEGNA A M,et al.Antineoplastic drug occupational exposure:A new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive buccal micronucleus cytome assay biomarker[J].Toxicol Lett,2019, 316:20-26. [49] HU J,ZHAO F,LIU L,et al.The meta-analysis of sister chromatid exchange as a biomarker in healthcare workers with occupational exposure to antineoplastic drugs[J].Medicine(Baltimore),2023,102(34):e34781. [50] NESS S L R,MASCARENHAS M Á,ARBO M D,et al.Occupational exposure assessment in professionals who manipulate and administer antineoplastic drugs in a university hospital in Southern Brazil[J].J Oncol Pharm Pract,2021,27(5):1205-1213. |